Produção Nacional
Revisado por pares
Vaccines and Treatments for Zika Virus Infection: Patent Status, Triumphs and Challenges
2021; Future Science Ltd; Volume: 10; Issue: 5 Linguagem: Inglês
10.4155/ppa-2021-0014
ISSN2046-8962
AutoresSandro G. Viveiros-Rosa, Wilson C. Santos,
Tópico(s)Insect behavior and control techniques
ResumoPharmaceutical Patent AnalystVol. 10, No. 5 EditorialVaccines and treatments for Zika virus infection: patent status, triumphs and challengesSandro G Viveiros Rosa & Wilson C SantosSandro G Viveiros Rosa *Author for correspondence: E-mail Address: sandrogvr@gmail.comhttps://orcid.org/0000-0002-5644-7181Programa de Pós-Graduação em Ciências Aplicadas a Produtos Para Saúde, Faculdade de Farmácia, Universidade Federal Fluminense, Niterói, Rio de Janeiro, BrasilInstituto Nacional da Propriedade Industrial, Divisão de Farmácia, Rio de Janeiro, Rio de Janeiro, Brasil & Wilson C Santos https://orcid.org/0000-0001-9971-094XPrograma de Pós-Graduação em Ciências Aplicadas a Produtos Para Saúde, Faculdade de Farmácia, Universidade Federal Fluminense, Niterói, Rio de Janeiro, BrasilDepartamento de Farmacología, Instituto Teófilo Hernando, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, SpainPublished Online:7 Sep 2021https://doi.org/10.4155/ppa-2021-0014AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: antibodiesclinical trialscongenital Zika syndromedrug repurposingneglected diseasespatent informationsofosbuvirvaccines – prophylacticZika virusReferences1. Abushouk AI, Negida A, Ahmed H. An updated review of Zika virus. J. Clin. Virol. 84, 53–58 (2016).Crossref, Medline, Google Scholar2. Viveiros-Rosa SG, Regis EG, Santos WC. Vector competence of Culex mosquitoes (Diptera: culicidae) in Zika virus transmission: an integrative review. Rev. Panam. Salud Publica. 44, e7 (2020).Crossref, Medline, Google Scholar3. Pan American Health Organization. Zika suspected and confirmed cases reported by countries and territories in the Americas cumulative cases, 2015–2017 (2017). https://www.paho.org/hq/dmdocuments/2017/2017-dec-21-phe-ZIKV-cases.pdfGoogle Scholar4. Ministério da Saúde do Brasil. Síndrome congênita associada à infecção pelo vírus Zika. Boletim Epidemiológico. Número especial (2019). https://portalarquivos2.saude.gov.br/images/pdf/2019/dezembro/05/be-sindrome-congenita-vfinal.pdf Google Scholar5. World Health Organization. WHO's response to Zika virus and its associated complications (2017). https://www.who.int/emergencies/zika-virus-tmp/response-zika-2017.pdf?ua=1 Google Scholar6. Lee BY, Alfaro-Murillo JA, Parpia AS et al. The potential economic burden of Zika in the continental United States. PLoS Negl. Trop. Dis. 11(4), e0005531 (2017).Crossref, Medline, Google Scholar7. Ministério da Mulher, da Família e dos Direitos Humanos: Governo Federal anuncia R$ 1.2 bilhão para pesquisas sobre dengue, Zika e chikungunya (2016). https://www.gov.br/mdh/pt-br/sdh/noticias/2016/marco/governo-federal-anuncia-r-1.2-bilhao-para-pesquisas-sobre-dengue-zika-e-chikungunya Google Scholar8. Viveiros Rosa SG, Fierro IM, Santos WC. Repositioning and investigational drugs for Zika virus infection treatment: a patent review. Expert Opin. Ther. Pat. 30(11), 847–862 (2020).Crossref, Medline, Google Scholar9. Poland GA, Ovsyannikova IG, Kennedy RB. Zika vaccine development: current status. Mayo Clin. Proc. 94(12), 2572–2586 (2019).Crossref, Medline, Google Scholar10. Gaudinski MR, Houser KV, Morabito KM et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomized, open-label, Phase I clinical trials. Lancet 391, 552–562 (2018).Crossref, Medline, CAS, Google Scholar11. Barrows NJ, Campos RK, Powell ST et al. A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe. 20(2), 259–270 (2016).Crossref, Medline, CAS, Google Scholar12. Mottin M, Borba JVVB, Braga RC et al. The A-Z of Zika drug discovery. Drug Discov. Today 23(11), 1833–1847 (2018).Crossref, Medline, CAS, Google Scholar13. Barton JH, Emanuel EJ. The patents-based pharmaceutical development process. JAMA 294(16), 2075–2082 (2005).Crossref, Medline, CAS, Google Scholar14. Sakakibara M, Brantetter L. Do stronger patents induce more innovation? Evidence from the 1998 Japanese patent law reforms. NBER Work. Pap. Ser. doi:10.3386/w7066 (1999) (Epub ahead of print).Google Scholar15. OXFORD UNIVERSITY INNOVATION LTD: WO2018020271 (2018).Google Scholar16. BHARAT BIOTECH INTERNATIONAL LIMITED: WO2017009873 (2017).Google Scholar17. World Health Organization. Zika epidemiology update (2019) (2019). https://www.who.int/emergencies/diseases/zika/zika-epidemiology-update-july-2019.pdf Google Scholar18. UNIVERSIDADE ESTADUAL DE CAMPINAS – UNICAMP: WO2019084640 (2019).Google Scholar19. EMERGENT BIOSOLUTIONS CANADA INC.: WO201944130 (2019).Google Scholar20. Tychan. Tychan successfully completes human safety studies for the first-in-class potent monoclonal antibody against Zika virus (2018). https://www.tychan.com/Tychan_Press_Release2_26October2018.pdf Google Scholar21. INST OF MICROBIOLOGY OF CHINESE ACADEMY OF SCIENCE: WO2018028635 (2018).Google Scholar22. THE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVI AND UNIV FLORIDA STATE RES FOUND AND UNIV JOHNS HOPKINS: WO2019075011 (2019).Google Scholar23. FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION INC: US2018117018 (2018).Google Scholar24. FLORIDA STATE UNIV RES FOUND INC.: US2017312257 (2017).Google Scholar25. THE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVI AND UNIV FLORIDA STATE RES FOUND AND UNIVERSITY OF PENNSYLVANIA: US2020197369 (2020).Google Scholar26. SUN YAT-SEN UNIVERSITY: CN107737133 (2018).Google Scholar27. GILEAD SCIENCES, INC.: WO2017184670 (2017).Google Scholar28. Gardinalli NR, Marchevsky RS, Oliveira JM et al. Sofosbuvir shows a protective effect against vertical transmission of Zika virus and the associated congenital syndrome in rhesus monkeys. Antiviral Res. 182, 104859 (2020).Crossref, Medline, Google Scholar29. RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY AND EMORY UNIVERSITY: WO2018111580 (2021).Google Scholar30. EMORY UNIVERSITY: WO2019113462 (2019).Google Scholar31. EMORY UNIVERSITY: WO2019173602 (2019).Google Scholar32. EMORY UNIVERSITY: WO2017189978 (2017).Google Scholar33. Clinical Trials.gov. A safety, tolerability, and efficacy of molnupiravir (EIDD-2801) to eliminate infectious virus detection in persons with COVID-19 (2020). https://clinicaltrials.gov/ct2/show/NCT04405570 Google Scholar34. UNIV TEMPLE: US20190093091 (2019).Google Scholar35. UNIV TEMPLE: WO2018071623 (2018).Google Scholar36. CREATIVE MEDICAL HEALTH: US20170296587 (2017).Google Scholar37. UNIV NANTONG: CN110693907 (2020).Google Scholar38. VOLUTION IMMUNO PHARMACEUTICALS SA: WO2017140903 (2017).Google Scholar39. UNIV MINNESOTA: US2020345826 (2020).Google Scholar40. CLEVELAND CLINIC LERNER RES INSTITUTE AND UNIV OF TEXAS MEDICAL BRANCH AND UNIV WASHINGTON: WO2018231690 (2018).Google ScholarFiguresReferencesRelatedDetailsCited ByRemdesivir: an overview of patenting trends, clinical evidence on COVID-19 treatment, pharmacology and chemistrySandro G Viveiros Rosa & Wilson C Santos31 May 2022 | Pharmaceutical Patent Analyst, Vol. 11, No. 2 Vol. 10, No. 5 Follow us on social media for the latest updates Metrics Downloaded 41 times History Received 15 July 2021 Accepted 13 August 2021 Published online 7 September 2021 Published in print September 2021 Information© 2021 Newlands PressKeywordsantibodiesclinical trialscongenital Zika syndromedrug repurposingneglected diseasespatent informationsofosbuvirvaccines – prophylacticZika virusFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)